CervoMed's Neflamapimod Shows Potential to Reverse Brain Atrophy in Lewy Body Dementia

Event summary

  • CervoMed presented MRI data at the 2026 AAN Annual Meeting showing neflamapimod increased basal forebrain volume and functional connectivity in dementia with Lewy bodies (DLB).
  • Right basal forebrain volume increased by 3.5% with neflamapimod treatment compared to a 4.2% decrease with placebo over 16 weeks.
  • Functional connectivity between the basal forebrain and default mode network improved by 46% during the extension phase.
  • CervoMed plans to initiate a global Phase 3 trial in DLB patients without Alzheimer's co-pathology in the second half of 2026, subject to financing.

The big picture

CervoMed's data suggests neflamapimod may be the first therapy to demonstrate potential reversal of basal forebrain atrophy in DLB, a condition with no approved treatments. The findings support the growing recognition of MRI as a sensitive biomarker for neurodegenerative diseases with prominent cholinergic deficits. If confirmed in Phase 3, this could represent a significant shift in treatment paradigms for DLB and other neurodegenerative disorders.

What we're watching

Clinical Validation
Whether the MRI biomarker data will accelerate regulatory discussions for neflamapimod's Phase 3 trial in DLB.
Financing Requirements
The pace at which CervoMed can secure funding for its planned Phase 3 trial, given its clinical-stage status.
Competitive Positioning
How these results position neflamapimod against emerging therapies targeting cholinergic dysfunction in DLB.